Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤$216.0 million cash balance expected to fund operations into 2029
- ➤Initial NKX019 clinical data in myositis and systemic sclerosis slated for ACR Convergence 2026
- ➤$33.3 million third-quarter net loss, or $0.45 per share
- ➤NKX019 dosing underway at 4 billion cells per dose across three doses
- ➤Ntrust enrollment continues across multiple autoimmune disease indications
Expert Statements
Paul J. Hastings, Chief Executive Officer of Nkarta
“NKX019 is advancing in our two lead indications, myositis and systemic sclerosis. We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando. We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients. With off-the-shelf availability and outpatient dosing at a growing network of community-based sites, our program is designed to deliver on that potential.”
* Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 * Cash balance of $216.0 million on September 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026.
"NKX019 is advancing in our two lead indications, myositis and systemic sclerosis," said Paul J. Hastings, Chief Executive Officer of Nkarta. "We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando. We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients. With off-the-shelf availability and outpatient dosing at a growing network of community-based sites, our program is designed to deliver on that potential."
Get started
Create a free account to read the full story.